Supreme Court Upholds 'Skinny Labels' for Generic Drugs in Favor of Hikma
The U.S. Supreme Court ruled unanimously in favor of generic drugmaker Hikma, allowing the use of narrower labels—known as 'skinny labels'—for generic drugs compared to their brand-name counterparts. The decision was a setback for Amarin Corp., which had argued against such labeling practices.
Topics: brand_name_drugs generic_drugs pharmaceuticals supreme_court